100% of study participants (n=25) achieved robust responses to oral mavorixafor
100% of neutropenic participants (n=14) achieved normalized neutrophil counts
Robust responses achieved across all CN disorders
X4 Pharmaceuticals Inc (NASDAQ:XFOR) updated its strategic priorities that include streamlining resources to focus on advancing its lead candidate, mavorixafor, in…